Studies were performed in in vitro and in vivo models to assess the effect of intravenous immunoglobulin (IVIG) on the development of acute complement-mediated tissue damage. IVIG significantly increased the duration of survival and frequently prevented the death of guinea pigs injected with anti-Forssman antiserum to cause lethal Forssman shock; no control animal treated with albumin and/or maltose vehicle survived. The most pronounced effect was achieve by delivering IVIG as one slow injection at 1,800 mg/kg 3 h before Forssman shock was elicited. Infusion of guinea pig IgG at the same dosage was similarly protective. A strong positive correlation was found between IgG plasma levels and survival time in guinea pigs treated with graded doses of IVIG. Therapy itself did not affect C3 and C4 levels nor the capacity to activate these components. In vitro studies showed almost complete inhibition of C3 uptake onto IgG-sensitized erythrocytes using serum from an IVIG-treated animal. We suggest that supraphysiologic levels of IVIG act in part by preventing active C3 fragments from binding to target cells. Infusion of high dose IVIG may be a rational approach to modulating acute, complement-dependent tissue damage in a variety of diseases in man.
Introduction
Forssman or heterophile shock is a well-studied immunopathological reaction produced by intravenous infusion of rabbit anti-Forssman antiserum into guinea pigs. It is characterized by hypotension, pulmonary edema, pulmonary hemorrhage, and death occurring within minutes after injection of the antiserum. Forssman shock has been classified as a type II reaction using the system of Coombs and Gell (1) . These The Forssman antigen is a lipopolysaccharide of 1,000 mol wt that is widely distributed in the tissues of guinea pigs (and many other species), where it is primarily situated in vascular endothelium and adventitial tissues (2). The antigen is absent from blood cells in the guinea pig, so intravenous administration of anti-Forssman antiserum results in antibody binding to endothelial cells in the first major capillary bed encountered, the pulmonary capillaries. The subsequent lethal reaction is mediated by the IgG fraction of the antiserum and is absolutely dependent upon complement activation via the classical pathway (3, 4) . Guinea pigs genetically deficient in C4 are insusceptible to Forssman shock until repleted with exogenous C4, whereupon reactivity is reconstituted (4) . Aggregation of platelets with or without mediator release may also have a role, but this is less well defined (5) . There is no histopathologic evidence for the involvement of neutrophils or other leukocytes, and profoundly neutropenic animals succumb readily to the same dose of antiserum as normals (6) .
In this study, marked prolongation of survival time and/or protection against death was achieved when guinea pigs were treated with high doses of human intravenous immunoglobulin (IVIG)' and then subjected to the injection of a lethal dose of anti-Forssman antiserum. Human serum albumin for intravenous use and low pH maltose injections (controls for exogenous human protein and the IVIG vehicle, respectively) did not extend survival of control animals. IVIG-treated animals' sera contained normal levels of complement C3 and C4, and demonstrated normal capacity to activate these proteins. However, sera from IVIG-treated animals showed markedly impaired capacity to deposit C3 fragments on IgG-coated targets in vitro. These observations may have a bearing on the mechanism of IVIG action in ameliorating immune complex and complement dependent inflammatory lesions.
Methods
Animals. Female 200-350-g guinea pigs (NIH multipurpose) were obtained from colonies maintained by National Cancer Institute at Frederick, MD.
Reagents. Human serum immunoglobulin for intravenous use in 10% maltose, pH 4 .25 (Gamimune), was purchased from Cutter Biologicals (Berkeley, CA). Human serum albumin 25% solution for intravenous administration was also obtained from Cutter Biologicals. (8) .
Anti-Forssman antiserum. Rabbit anti-Forssman antisera were prepared by previously described methods using boiled sheep erythrocyte stromata as the antigen source (9) . Hemolytic antibody titration was performed by the method ofMayer (10) . Two batches ofantiserum with different titers were used. The lethal dose of the heat-inactivated anti-Forssman antiserum (minimum amount of serum required to kill 100% of normal guinea pigs weighing 350-500 g in 10 min or less) was determined from the results of the preliminary experiments and was found to be 1.15 gl/g ofbody weight for lower titer batch ofantiserum, and 0.45 yI/g for the higher titer batch. However, both were uniformly lethal at the doses noted.
Antibodies. Rabbit polyclonal IgG anti-guinea pig C3 was purified from the sera of rabbits repeatedly immunized intravenously with purified guinea pig C3 in Freund's adjuvant. Rabbits repetitively immunized with whole, washed guinea pig erythrocytes served as the source of anti-erythrocyte antibody used for in vitro C3 binding studies. IgG fractionation of these sera included sequential ammonium sulfate precipitation, Sephacel G-200 sieving chromatography and DEAE anion exchange chromatography. FITC labeled affinity-purified goat immunoglobulins specific for rabbit IgG and guinea pig C3 was obtained from Kirkegaard & Perry Laboratories, Inc. (Gaithersburg, MD).
Radiolabeling of antibodies. Radioiodination of rabbit IgG antiguinea pig C3 was accomplished using the Iodobeads method. Briefly, 300 mg of IgG was incubated with 1 mCi of 251 (Amersham Corp.), and three Iodobeads for 30 min with occasional agitation at room temperature. Free iodine was then separated from protein-bound isotope by passing the labeled material through a prepacked PD IO (Sephadex G-25M) column (Pharmacia Fine Chemicals, Piscataway, NJ) that had been preequilibrated in isotonic PBS, pH 7.4.
IVIG treatment-3-d protocol. Guinea pigs were anesthetized with Rompun (Xylazine; Mobay Corp., Shawnee, KS) followed by Vetalar (Ketamine HC1; Parke-Davis Co., Morris Plains, NJ) and then infused via a hind limb vein with the desired doses of immunoglobulin, albumin or 10% maltose solution, pH 4.25, for three consecutive days. On day 4, 24 h after the last injection, Forssman shock was provoked.
IVIG treatment-one injection protocol. Guinea pigs were anesthetized as usual and then very slowly infused with a single dose ofhuman IVIG or albumin equivalent to that given over the period of 3 d. The human serum albumin was predialyzed such that both proteins were delivered in 10% maltose, pH 4.25. 3 h after the injection, when the animals had recovered from anesthesia, Forssman shock was elicited. Experiments using guinea pig IgG instead of human IVIG were carried out using the same protocol.
Forssman shock. Forssman shock was induced by injection of a predetermined lethal dose of rabbit anti-Forssman antiserum into the hind limb vein of guinea pigs. The symptoms seen in these animals were as follows: rubbing of the nose, labored breathing, sneezing, coughing, prostration, and death, usually evolving rapidly over 2 to 7 min. Blood samples were taken by retroorbital sinus puncture before and after shock in order to measure C3, C4 Complement titrations. Hemolytic complement titrations ofguinea pig C4 and C3 were performed using standard published procedures (7) .
Levels ofhuman IgG in guinea pig sera. Concentrations of human IgG in guinea pig sera were determined using radial immunodiffusion plates (AccraAssay; ICN Immunobiologicals, Lisle, IL) and known calibrating standards. These plates gave no significant reactivity with guinea pig sera alone.
In vitro C3 binding studies. Two-tenths of 1 ml of guinea pig erythrocytes at 2.7 X 108 cells/ml were incubated with 0.1 ml ofdiluted rabbit IgG anti-guinea pig erythrocyte antibody or 0.1 ml of buffer for 30 min at 370C. A series of separate reaction tubes containing buffertreated unsensitized guinea pig erythrocytes (E) or antibody sensitized guinea pig erythrocytes (EA) were prepared and the cells were washed and pelleted. 400 gl of undiluted normal guinea pig serum, sera from animals treated with graded doses of IVIG in one injection (600, 1,200, and 1,800 mg/kg), and serum from an animal treated with albumin/ maltose in volumes equivalent to IVIG at 1,800 mg/kg, were each added to one pair of EA and E tubes. The tubes were placed in a water bath at 370C. At 0, 2, 5, 15, and 30 min, duplicate 40-ul samples were taken from each tube and transferred to wash tubes with ice-cold EDTA buffer. The intact erythrocytes in these samples were pelleted and the extent of lysis was determined by measuring free hemoglobin in the corresponding supernatants spectrophotometrically. The pellets were then washed again and resuspended in 200 ,ul ofGVBS2+. 10 Ml of '251-labeled rabbit IgG anti-guinea pig C3 was added to each tube and the mixture incubated for 60 min at 0C. After two further washes in ice-cold EDTA buffer, the pellets were counted in a gamma counter. Where appropriate, counts were corrected for the calculated percentage of hemolysis. Preliminary studies showed that results obtained by mathematically correcting for lysis closely paralleled those obtained using serum immunodepleted of C8 and thus incapable of hemolysis (11) . In another series of experiments, guinea pig erythrocytes at 2.7 X 108 cells/ml were sensitized with rabbit IgG anti-guinea pig erythrocyte antibody diluted in SGVBS2+; one portion ofthese cells was incubated with partially purified guinea pig Cl component (5,000 hemolytic U/ml) for 15 min at 30°C and washed twice in SGVBS2+ (EAC 1). One aliquot of EAC 1 was then further treated with purified human C4 (5,000 hemolytic U/ml) for 45 min at 37°C (EAC1,4). 100-Al aliquots of EA, EAC 1, and EAC 1,4 were pelleted and then resuspended in 200
Al of normal guinea pig serum, heat-inactivated guinea pig serum, and serum from a guinea pig treated with IVIG, 1,800 mg/kg. The tubes were placed in a 37°C water bath, duplicate 40-ul samples were taken at 5-and 30-min time points and transferred to wash tubes with icecold EDTA buffer. C3 uptake was quantified with radiolabeled anti-C3 as described above and counts were corrected for lysis.
Results
Effect ofIVIG on survival in Forssman shock. The initial experimental group of animals (n = 10) was treated for three consecutive days with infusion of human IgG at 600 mg/kg i.v., a protocol yielding a final total dose similar to that employed in human ITP (12). Two control groups were treated in parallel. The first group (n = 8) received 10% maltose in water, pH 4.25, at volumes equivalent to those delivered to the experimental group, while the second control group (n = 7) was infused for 3 d with 25% human albumin for intravenous use at 600 mg/kg. Forssman shock was provoked on the fourth day by injection of anti-Forssman anti-serum at 1.15 Al/g. As shown in Fig. 1 Forssman shock by injection of a lethal dose of anti-Forssman antiserum. A more potent anti-Forssman anti-serum was used in this series; median survival time of entirely untreated animals was 2 min. Pretreatment with IVIG prevented death in 38% of animals and markedly increased the duration of survival in those IVIG treated animals that did succumb (Fig. 2) . All control animals died within 4 min after the injection of anti-Forssman antiserum. The differences in survival of the two groups were highly significant when analyzed by the Wilcoxon test (P < 0.001).
To examine the possibility that the IVIG effect resulted from the heterologous source of IVIG, lyophilized guinea pig IgG and albumin were reconstituted with distilled water; maltose was added to make 10% solutions and the pH of each was brought to 4.25 with 1 N HCL. Six guinea pigs were anesthetized; four animals were slowly infused with guinea pig IgG at 1,800 mg/kg; two received guinea pig albumin at the same dose. 3 h after these infusions all animals were injected with 0.4 ul/g of anti-Forssman antibody. Animals treated with guinea pig albumin died within 2 min whereas among guinea pig IgG-treated animals two survived and the two that eventually succumbed to Forssman shock lived for 15 and 20 min, respectively, after provocation.
Dose-response of survival and levels of human IgG in guinea pig sera. Three groups ofanimals (n = 4 in each group) were treated with increasing doses of IVIG (600, 1,200, and 1,800 mg/kg) using the one-injection protocol. Control animals (n = 9) were infused with the same volume of maltose solution as required for 1,800 mg/kg of IVIG, containing instead 1,800 mg/kg of human albumin. 3 h later, Forssman shock was provoked. A stepwise enhancement of survival was seen in the groups receiving 1,200 and 1,800 mg/kg, whereas the 600-mg/kg group was not markedly different from controls (Fig. 3 a) . When survival time was studied as a function of the concentration of human IgG obtained in the animals' sera, a strong positive correlation was found between these parameters by the Spearman rank correlation method (Spearman's rho = 0.92, P < 0.001, see Fig. 3 b) . To Titers ofC3 and C4 before and after provocation ofForssman shock. In our initial studies, blood samples for C3 and C4 titers were taken before treatment, before Forssman shock and at various time points after shock to assess whether IVIG altered overall complement consumption. Infusions of IVIG, maltose, and/or albumin had no effect on C3 and C4 titers, since pretreatment and preshock values remained totally unchanged (data not shown). This finding confirmed our previous observations with IVIG in a guinea pig model (1 1). After the injection of anti-Forssman antiserum, the average percentage of C3 and C4 consumed was not significantly different between the various controls and IVIG treated group of animals when assessed by thef-test (Table I) . To assess the possibility of a difference in the kinetics of complement consumption after the injection of anti-Forssman antiserum, regularly timed blood samples were collected (before shock and 1, 2, 4, 8, and 60 min after shock) for C3 and C4 titers in one group of maltose/albumin-treated animals and one group of guinea pigs injected with 1,800 mg/kg of IVIG 3 h before shock. As shown in Fig. 4 , plasma C3 and C4 titers fell precipitously in IVIGtreated animals 1 min after injection of anti-Forssman antiserum and remained essentially unchanging for at least 7 min thereafter. C4 and C3 were consumed to an identical extent in control animals at 1 min, then plateaued at 2 min, again at levels not distinguishable from IVIG-treated animals. Despite the apparent lack of progressive complement consumption after 1 min, all controls died before 4 min. Their overall extent of complement C3 and C4 consumption at 2 min was not different from that observed at death in all other animals, treated on the same protocol and receiving the same antiForssman preparation (30.1±6.6% for C3, and 61.6±15.6 for C4). In IVIG-treated long-term survivors, some further consumption of complement was noted at the 60-min point.
Thus, these survivors actually sustained greater total complement consumption than their control counterparts.
Immunohistochemistry. Lung tissue specimens taken postmortem from animals treated with IVIG and maltose/albumin were immediately frozen and cut into 6-,gm thick slides. Tissue slides were incubated with FITC-labeled goat anti-rabbit IgG. It is evident from Fig. 5, A and B that anti-Forssman IgG antibody was deposited in the pulmonary parenchyma, presumably on endothelial and connective-adventitial cells, in both IVIG-infused animals and controls. Normal guinea pig lung tissues or tissues stained with FHTC-labeled goat antimouse IgG showed no fluorescence. Lung tissue from animals infused with IVIG and not subjected to Forssman shock and tissue from animals receiving nonimmune rabbit serum were likewise negative (Fig. 5 C) . Thus, IVIG did not appear to act by blocking anti-Forssman IgG uptake in the lung. Evaluation of sections stained with anti-C3 was more difficult. All control tissues, including totally normal lung, showed significant background staining. While tissues from animals dying of Forssman shock showed distinctly stronger staining, it was not possible to ascertain whether IVIG treatment altered C3 deposition. To Albumin pretreatment had no impact on C3 uptake. sitized with rabbit anti-guinea pig erythrocyte antibody were incubated with undiluted normal guinea pig serum, serum obtained from animals treated with increasing doses of IVIG and serum from an animal injected with albumin in maltose. At various time points, aliquots were removed to quantitate C3 binding by uptake of 1251 anti-guinea pig C3 onto the sensitized erythrocytes. At all time points IVIG almost completely suppressed the uptake of C3 (Fig. 6 A) . Albumin/maltose treatment had no effect whatever on C3 uptake relative to the normal guinea pig serum (Fig. 6 B) . The same phenomenon was observed in another in vitro experiment in which IgGsensitized erythrocytes were sensitized stepwise with purified Cl and C4 complement components and then incubated with normal guinea pig serum, heat inactiveated guinea pig serum and serum from an animal treated with 1,800 mg/kg of IVIG. CI followed by C4 (o) were incubated at 370C with normal guinea pig serum (1, 4, 7) , heatinactivated guinea pig serum (2, 5, 8) and serum from an animal pretreated with IVIG at 1,800 mg/kg (3, 6, 9) . Duplicate samples were taken at 5-min and 30-min time points. C3 uptake was monitored by binding of radiolabeled anti-C3. The uptake of C3 was inhibited at both 5-(shown here) and 30-min (not shown) time points to virtually background levels by the serum from an IVIG-treated animal. The effect was maintained or enhanced by preloading the cells with C I and C4, suggesting that the action of IVIG occurred primarily at the C3 convertase or C3 binding step(s).
In all instances the C3 uptake, as measured by binding of radiolabeled anti-C3 antibody at 5-and 30-min time points, was inhibited to almost background levels (Fig. 7) . That preloading the target cells with C1 and/or C4b residues did not reduce (and indeed enhanced) the IVIG effect suggested that the primary influence of IVIG was not at either of these potential interference points.
Discussion
Intravenous immunoglobulin has been shown to be effective in treating idiopathic thrombocytopenic purpura and a variety ofother antibody-mediated autoimmune diseases. The mechanism of action is unclear, but it has been suggested that IVIG inhibits the binding of IgG-coated targets to phagocytic cells expressing IgG Fc receptors. We have explored the effect of IVIG on complement activation and on target tissue deposition. In a previous study (1 1), we found that IVIG suppressed complement-dependent clearance of particulate immune complexes in an in vivo system free of IgG-Fc receptor interactions. Our results suggested that IVIG may interfere with complement C3 fragment deposition onto IgM-sensitized erythrocytes, and that this could be an important mechanism of action of IVIG in immune cytopenias. We speculated that IVIG might be a more effective complement activation modulator in an IgG-dependent model, especially in view of the higher densities of target-bound IgG required, relative to IgM, to initiate efficient complement activation (13) . To examine this possibility, we chose Forssman shock, an in vivo model of tissue damage, which is complement dependent and IgG mediated. In spite of the long history of research on Forssman shock, the exact mechanisms involved are still not known.
There is a general agreement among investigators that antiForssman antibodies of IgG class react with antigenic determinants on pulmonary endothelial cells, triggering the complement cascade and ultimately leading to endothelial cell damage in Forssman shock. In this respect it is similar to the postulated pathophysiologic mechanism of Kawasaki disease ( 14) , the vasculitic pathology which is responsive to IVIG therapy (15) . The requirement for an intact classical pathway of complement activation is absolute, and there is no convincing evidence that cellular Fc receptors participate in any way in the pathogenesis of the lesion.
In the present study, infusions ofhigh doses of IVIG significantly increased survival time and/or prevented death in guinea pigs subjected to Forssman shock. No control animal (treated with albumin and/or maltose) survived injections of lethal doses of anti-Forssman antibodies. In addition, experiments in which animals were treated with high doses ofguinea pig IgG and albumin proved that the same protective phenomenon was operative in a homologous system. The effect of IVIG on survival in Forssman shock was significant when the immunoglobulin was administered over 3 d, but was even more striking when the dose of IVIG was administered in one slow injection and Forssman shock elicited a few hours later. This finding is most probably due to the higher plasma levels of human IgG obtained by this latter protocol. Presumably, the majority of the infused IgG remained within the intravascular space after a one-dose infusion, while over the longer period of the 3-d protocol it distributed to both the extra and intravascular space, with resultant lower plasma levels (mean human IgG level = 8.7 mg/ml). The effectiveness of the one dose protocol and the dependance of effect on IVIG plasma levels was further supported by the results ofthe experiment in which graded doses of IVIG were given by the single dose protocol. We found a strong positive correlation between the survival time and concentration of human IgG obtained in animals' sera. This result was confirmed within each subgroup, suggesting that the correlation was not an artifact of group-togroup variation in the pooled data.
We considered several possible mechanisms of IVIG effect in Forssman shock. No decrease in serum complement titers was found in IVIG-treated animals before shock. Thus, protective decomplementation before shock was not responsible for the effect noted. Interference with the binding of antiForssman antibodies to target cells in the pulmonary vascular bed or parenchyma was also deemed unlikely based on the results of our immunohistochemical study. In both control animals and animals treated with IVIG, FITC-labeled goat anti-rabbit IgG reacted strongly with pulmonary parenchymal endothelial and adventitial cells. Multiple control experiments were performed to rule out various unexpected competitive antigen-antibody interactions. These included adsorption of human IVIG with sheep erythrocytes to remove any competitive anti-Forssman antibodies, premixing of anti-Forssman antisera with IVIG, and adsorption of anti-Forssman antisera with insolubilized guinea pig serum proteins. None of these maneuvers altered the expected effectiveness of the IVIG or the lethality of the anti-Forssman antibodies. Blockade of complement activation per se also plays no role in IVIG effect in Forssman shock, since the percentage of C3 and C4 consumed at various time points following provocation of shock was not different in IVIG treated animals compared to animals treated with albumin and maltose. In fact, in IVIGtreated long-term survivors these complements continued to be gradually consumed at later time points. The cytotoxic effects of complement activation hinge on the deposition of early activation products, notably C4b and C3b, onto target surfaces. These target-bound residues serve as an obligate nidus for the assembly of the membrane attack complex and also may localize the production of such complement-derived mediators as the anaphylatoxins (16 (22) . Additional support was obtained using a solid-phase assay system. Microplate wells were coated with immune complexes prepared from human albumin and rabbit anti-human albumin IgG. Exposure ofthese wells to normal human serum supplemented with IVIG to 20 mg/ml, resulted in 60% inhibition of C3 binding (as measured by uptake of radiolabeled anti-human C3) in the presence of IVIG. Taken together with the vigorous consumption of C4 and C3 noted in IVIG-treated animals submitted to Forssman shock, these data suggest that the presence of high levels of IVIG may indeed divert complement activation products from target surfaces without blocking activation per se.
Further studies are necessary to completely elucidate the mechanism of IVIG action in prolonged survival in Forssman shock. These will include assessment of the formation of human IgG-guinea pig C3b complexes after the injection of anti-Forssman antibodies and studies of cytotoxicity and complement fragment uptake in an in vitro system using cultured endothelial cells as targets for anti-Forssman antibodies. Nonetheless, the data presented here indicate that IVIG in very large doses may represent a useful therapeutic agent to modify acute complement-dependent tissue damage. IVIG is a natural product with remarkably little toxicity. Our findings provide a novel potential theoretical basis for the reports of rapid improvements in active vasculitic syndromes such as Kawasaki disease (15) , or antibody and complement-dependent skin disease such as bullous pemphigoid after IVIG (23) and suggest that administration of IVIG in even higher doses than currently used be formally evaluated.
